As previously reported yesterday afternoon, Canaccord upgraded Vertex Pharmaceuticals (VRTX) to Hold from Sell with a price target of $424, up ...

Truist raised the firm’s price target on Vertex Pharmaceuticals (VRTX) to $520 from $460 and keeps a Buy rating on the shares. The firm is ...

US Federal officials have approved a new pain pill by Vertex Pharmaceuticals called Journavx, aimed at reducing addiction and ...

The company posted quarterly adjusted earnings of $3.48 per share which missed the analyst consensus estimate of $4.03 per ...

A non-opioid pain medication made by Vertex Pharmaceuticals has received approval for adults from the Food and Drug ...

Vertex Pharmaceuticals dominates the market for cystic fibrosis drugs, but Sionna Therapeutics contends the pharma company’s products still have efficacy and safety limitations. Sionna has ...

NOW OPEN: 200 Charter Memberships to Benzinga Trade Alerts Vertex Pharmaceuticals Inc. VRTX shares are trading higher Friday following two major developments that strengthen its position in both ...

Vertex Pharmaceuticals stock (NASDAQ: VRTX) is trending higher after the U.S. FDA approved Journavx – an oral non-opioid pain medication. This is a big win for Vertex, given that Journavx can ...

Biotech company Vertex Pharmaceuticals (NASDAQ:VRTX) will be reporting results tomorrow afternoon. Here’s what to look for. Vertex Pharmaceuticals beat analysts’ revenue expectations by 3.2% ...

Financial giants have made a conspicuous bearish move on Vertex Pharmaceuticals. Our analysis of options history for Vertex Pharmaceuticals (NASDAQ:VRTX) revealed 10 unusual trades. Delving into ...